Article
Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations.
Blood - 31 Mar 2011
Jabbour Elias, Cortes Jorge, Santos Fabio P S, Jones Dan, O'Brien Susan, Rondon Gabriela, Popat Uday, Giralt Sergio, Kebriaei Partow, Jones Roy B, Kantarjian Hagop, Champlin Richard, de Lima Marcos
Abstract excerpt
Hematopoietic stem cell transplantation (HSCT) is effective therapy for patients with chronic myelogenous leukemia (CML) but is now mostly indicated for patients who develop resistance to tyrosine kinase inhibitors (TKIs), which can be associated with point mutations in BCR-ABL1. We reviewed the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.